Galecto (GLTO) Registration Filing summary

Company overview and business model

• Focuses on developing therapies for hematological malignancies, particularly myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML).

• Pipeline includes DMR-001, DMR-002, DMR-003 (mutCALR-targeted antibodies), and GB3226 (dual ENL-YEATS/FLT3 inhibitor).

• Acquired Damora Therapeutics and assumed rights under the Paragon Option Agreement for antibody discovery and development.

• Collaborates with Paragon and Paramora for research, with options to license and commercialize resulting antibodies.

Financial performance and metrics

• Reported net losses of $3.1 million for the three months and $9.1 million for the nine months ended September 30, 2025.

• Accumulated deficit of $286.6 million as of September 30, 2025.

• As of November 30, 2025, held $274 million in cash and cash equivalents, expected to fund operations into 2029.

• Completed a $285 million private placement of Series C Preferred Stock in November 2025.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by selling stockholders; all proceeds go to selling stockholders.

• Proceeds from the PIPE were used to strengthen the balance sheet and support ongoing R&D and clinical development.

• Ongoing payments to Paragon for research, development, and milestone fees under the Paragon Option Agreement.